Evidence map›Paper›PMID 31666599›Full record

ArticleScientific reports2019

mRhubarb: Engineering of monomeric, red-shifted, and brighter variants of iRFP using structure-guided multi-site mutagenesis.

Oliver C Rogers, Dorothy M Johnson, Elad Firnberg

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
3.5field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 20 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Rapid directed molecular evolution of fluorescent proteins in mammalian cells.Protein science : a publication of the Protein Society · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Oliver C RogersRevolve Biotechnologies, Inc., Baltimore, MD, USA.
Dorothy M JohnsonRevolve Biotechnologies, Inc., Baltimore, MD, USA.ORCID http://orcid.org/0000-0003-0036-996X
Elad FirnbergRevolve Biotechnologies, Inc., Baltimore, MD, USA. elad@revolvebiotech.com.
Refuge Biotechnologies (United States) · US

Funding

iRFP-Max: A novel infrared fluorescent protein for deep tissue imagingR43MH108308 · NIMH · REVOLVE BIOTECHNOLOGIES, INC. · PI FIRNBERG, ELAD · 2015 to 2015
$448k
NIMH NIH HHS R43 MH108308
6 · The paper itself

Abstract

Far-red and near-infrared fluorescent proteins (FPs) enable in vivo tissue imaging with greater depth and clarity compared to FPs in the visible spectrum due to reduced light absorbance and scatter by tissues. However current tools are limited by low brightness, limited red-shifting, and a non-ideal dimeric oligomerization state. In this study we developed a monomeric variant of iRFP, termed mRhubarb713, and subsequently used a targeted and expansive multi-site mutagenesis approach to screen for variants with red-shifted spectral activity. Two monomeric variants were discovered, deemed mRhubarb719 and mRhubarb720, with red-shifted spectra and increased quantum yield compared to iRFP. These tools build on previously developed near-IR FPs and should enable improved in vivo imaging studies with a genetically encoded reporter.

Indexed as

Genetic VariationMutagenesisColorComputer SimulationLuminescent ProteinsModels, MolecularPlasmidsProtein ConformationProtein EngineeringRed Fluorescent ProteinLuminescent ProteinsRed Fluorescent Protein

Identifiers

PMID31666599
PMCPMC6821797
OpenAlexW2982360150

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.